360° Coverage : Accessing The Pharmaceutical And Medical Device Markets In...

2 Updates

Accessing The Pharmaceutical And Medical Device Markets In Myanmar

May 12 2014, 11:23am CDT | by

When Myanmar opened to the West, one of the first sectors multinationals were most excited to pursue was the healthcare market. Because of the country’s internally forced exile from the world’s...

Filed under: news

 
 
 

22 weeks ago

Accessing The Pharmaceutical And Medical Device Markets In Myanmar

May 12 2014, 11:23am CDT | by

When Myanmar opened to the West, one of the first sectors multinationals were most excited to pursue was the healthcare market. Because of the country’s internally forced exile from the world’s stage, Myanmar’s healthcare system has long been starved of western pharmaceuticals, medical devices and diagnostic equipment. Currently, Myanmar’s government-supported public healthcare provides basic care and some acute disease management; however, the little bit of capacity that is available is sporadic. For the last several decades, the WHO, UN and various NGOs have all made up the difference between what a functioning public healthcare system should have been able to provide – in particular with respect to communicable diseases – and what little the government system was actually capable of delivering. Historically, Myanmar’s government has spent approximately 2% of its Gross Domestic Product (GDP) on healthcare; impoverished Laos spends 4.5% and Cambodia 5.6%.  As a result of Myanmar’s inadequate spending on healthcare, the WHO ranked Myanmar’s healthcare system dead last out of the 190 countries ranked with respect to “overall health system performance.”

Roughly a year ago, when we completed the first survey of Myanmar’s healthcare system, it was already obvious that in the country’s biggest cities consumers were interested and expressing a willingness to pay for higher-quality western medicines.  We sat down with consumers in markets, doctor’s offices and clinics to complete our survey. Most of the interviewees expressed broad confidence in the care they receive from their local doctors. Families also had a strong preference to pay more money if they could get their hands on western medicine. Not surprisingly, these expectations were related to their belief that western therapeutics would be of higher quality and have more efficacy than those they could buy from local producers.  But, as multinationals know all too well in emerging economies, while the consumer’s appetite for western healthcare is an important trigger for growth, on its own this desire is inadequate to drive meaningful commercial success. Within a country like Myanmar, several other pieces have to be in place for sustainable success.

First, as I shared last week, most policy analysts watching Myanmar are quick to point out, the country continues to struggle with a handful of unresolved political questions that have the potential to prove destabilizing, at least in the short-to-mid term.  Chief among these are the ethnic and religious divides in the country’s northern region, long-standing and still unresolved issues that occasionally present themselves even in Myanmar’s larger cities.  Thus far the response of the current government has been reasonably even-handed, which reflects a realization on its part that the country needs stability in advance of the upcoming 2015 presidential election, an event outsiders are closely watching as a means to gauge Myanmar’s political stability and whether new foreign direct investment makes sense.

Second, sustainable success in Myanmar requires the local economy to grow.  While government spending on healthcare is increasing, much of what will drive the growth for multinationals in Myanmar will be out of pocket spending by individual consumers. Consequently, their ability to pay for western medicine is directly related to the country’s economic growth. The World Bank estimates that Myanmar’s GDP growth between 2012-2013 was 6.5%, while the Asian Development Bank projects that economic growth should be 7.8% over the next two years.  This growth is being driven primarily by foreign investments in energy, infrastructure and transportation.  Jovi Seet, who manages PriceWaterhouseCooper’s efforts in Myanmar, noted that foreign direct investments into Myanmar are thus far being directed at many of the country’s longest standing problem areas:  “If you think about where the country most needs development – physical infrastructure, power, connectivity – there has been improvement in allowing FDI in these areas.”  Additional reforms in the country’s FDI laws should further accelerate inbound investment over the course of the next several years, assuming the political transition remains peaceful and orderly.

Third, for multinational healthcare companies, the Myanmar government’s expanded funding for healthcare over the last twelve months is an important signal for further investment.  When we were in the country, it was encouraging to hear broad agreement from the Ministry of Health that money was being re-allocated towards healthcare. Since then, the country’s FDA has received significant new funding which has greatly expedited new drug registration, allowing multinationals to get new products into Myanmar more quickly than before.  There are many calls on this funding, and one of the more pressing questions is how to reinforce Myanmar’s public health administration such that new investments are wisely made, and best directed at what will benefit the country’s people.

Dr. Varun Sethi, General Manager for DKSH Healthcare’s business in Myanmar, one of the largest distributors for multinational pharmaceuticals, consumer health and medical devices in the country, recently shared with me that he sees the growing government-led spending on pharmaceuticals as the most encouraging sign.  Dr. Sethi pointed out, “Over the last year, we have seen the Ministry of Health expand and formalize the tendering process in public hospitals, albeit in a decentralized fashion.  This process began in 2012, but funding was limited to roughly USD 8 million.  In the 2013 fiscal year that ended on March 31, 2014, government estimates put that number at USD 40 million and the next phase beginning this fiscal year will see the public hospital pharmaceutical tenders grow to an estimated USD 70 million.”

Accessing this market is obviously key, which is the fourth key to sustainable success in Myanmar; namely, having competent local distribution. Early pharmaceutical and medical device entrants such as GE Healthcare, GSK and Roche, have all made investments in cultivating local training and distribution in an effort to first identify key stakeholders within the healthcare system and government.  As anyone with experience in emerging economies in general knows, in-country success many times relies on relationships and trust. We found that for the handful of multinational companies who had extensively expanded into Myanmar, their success was tied to the quality of their distribution partner. The market is highly fragmented, with multiple points of sale that are rarely immediately obvious to a foreign company.  Dr. Sethi pointed out that in his experience, many multinationals are coming to understand that in Myanmar “success is not a slam dunk – before they can get a ton of business they need to pay attention to some basic issues like registration which can delay and unnecessarily complicate their ability to sell into Myanmar.”

Overall, Dr. Sethi and other pharma companies we interviewed who are early into their pursuit of a domestic market in Myanmar remain positive about the ability of multinationals to be successful in Myanmar. In a short span since 2012, when the current reforms began under the U Thein Sein government, local consumers have had access to more choice than ever before and not just for healthcare products. As Dr. Sethi pointed out, “since the market has opened up, consumers have a lot of choice on different ways to spend their money – not everything is going to healthcare – now they have options they never had in telecommunication, consumer appliances and general consumer goods.  While they are doing better economically, their purses have not expanded as quickly as their choices on what to spend the money they have.”

For Myanmar’s healthcare system to begin clawing its way forward, there are at least four structural changes that will be necessary.  First, the public financing schemes that fund government provided healthcare will need to be reformed and funded.  Second, the Ministry of Health will need to ensure there are not too many competing agenda items without clear priorities on where limited money is going to be spent.  Third, FDI policies need to be developed specific to healthcare, in particular hospitals and domestic pharmaceutical manufacturing of basic formulary medicines.  Fourth, major efforts to modernize the country’s medical schools will need to take shape.  Reflecting these challenges, multinationals selling in Myanmar will need to continue to invest in local distribution, marketing and relationship-building among doctors, pharmacists and dealers who have historically been not only key points of sale in the country, but also trusted by consumers to differentiate between products and manufacturers. While today the narrative about Myanmar’s potential may have gotten a bit ahead of the actual facts on the ground, the country’s underlying strength is built on strong and diverse natural resources, a young and able workforce and a deep desire to again become part of the global economy.

 
Update
2

7 weeks ago

Khazanah throws MAS RM6b lifeline

Aug 29 2014 5:01pm CDT | Source: Business Times Singapore

August 30, 2014 1:15 AMKHAZANAH Nasional will inject RM6 billion (SS$2.4 billion) over three years to resuscitate loss-making Malaysia Airlines (MAS) under a recovery plan that includes even an Act of Parliament. Other key moves are migrating its operations, assets and liabilities to a new company (NewCo) and slashi ...
Source: Business Times Singapore   Full article at: Business Times Singapore
 

 
Update
1

7 weeks ago

MAS posts loss of RM307m for Q2

Aug 28 2014 5:00pm CDT | Source: Business Times Singapore

August 29, 2014 1:13 AMMALAYSIA Airlines (MAS) registered a loss of RM307 million (S$122 million) for the second quarter to end-June, but warned of worse to come in the second half when the "full financial impact of the double tragedies of MH370 and MH17" hits ho ...
Source: Business Times Singapore   Full article at: Business Times Singapore
 

 

Don't miss ...

 

<a href="/latest_stories/all/all/30" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

blog comments powered by Disqus

Latest stories

China stocks open higher
Beijing, Oct 20 (IANS) Chinese stocks opened higher Monday with the benchmark Shanghai Composite Index opening at 2,346.05 points, up 4.87 points, or 0.21 percent.
 
 
US defence department to create medical team for Ebola
Washington, Oct 20 (IANS) The US Department of Defense said Sunday the military is creating a 30-member team which will be tasked with providing emergency assistance in case of Ebola virus infection in the country.
 
 
Israel's Tamar gas field to sell gas to Egypt
Jerusalem, Oct 20 (IANS) Israel's Tamar gas field announced Sunday they have signed a bid to sell at least five billion cubic meters of natural gas over three years to private consumers in Egypt.
 
 
Liberian president calls for global support to fight Ebola
Monrovia, Oct 20 (IANS) Liberian President Ellen Johnson Sirleaf Sunday called on the international communities to join the country to fight the Ebola virus disease.
 
 
 

Latest from the Network

Bush shoe-tossing painting hits record at Doha auction
Doha, Oct 15 (IANS/EFE) A controversial painting by Iranian artist Mahmud Obaidi, depicting an Iraqi journalist throwing shoe in 2008 at then US president George W. Bush, was sold for $62,500 at a Sotheby's auction in...
Read more on Celebrity Balla
 
US offers $45 mn bounty for eight terror leaders
Washington, Oct 15 (IANS) The US said Tuesday it is offering rewards totalling up to 45 million dollars for information on eight key leaders of the Al Qaeda in the Arabian Peninsula (AQAP) terrorist organisation. The...
Read more on Politics Balla
 
UNSC extends peacekeeping mission's term in Abyei
United Nations, Oct 15 (IANS) The UN Security Council (UNSC) has renewed the mandate of the UN peacekeeping mission in the Abyei border region between Sudan and South Sudan. In an unanimously adopted resolution, the...
Read more on Politics Balla
 
Ebola cases in West Africa could reach 10,000 per week: WHO
Geneva, Oct 15 (IANS) The World Health Organisation (WHO) has warned that the Ebola epidemic in West Africa could reach 5,000 to 10,000 cases per week by the first week of December. "Quite frankly, ladies and...
Read more on Business Balla
 
Turkey, Singapore sign strategic partnership agreement
Ankara, Oct 15 (IANS) Turkey and Singapore have signed a strategic partnership agreement to boost economic, political and cultural cooperation, as well as security collaboration, during the official visit of...
Read more on Politics Balla
 
Christina Aguilera is returning to 'The Voice' USA
Christina Aguilera will return to 'The Voice' USA next year. The 'Your Body' hitmaker, who previously shared a rotating spot on the judging panel with Shakira, has been replaced by Gwen Stefani this season as she is...
Read more on Celebrity Balla
 
Kesha's music producer hits back
Kesha is being countersued by her record company boss, Dr. Luke. The 41-year-old music producer, who runs Kemosabe Records, claims the 27-year-old 'Tik Tok' singer is a liar and is trying to extort him after she accused...
Read more on Celebrity Balla
 
Jason Derulo won't get back together with Jordin Sparks
Jason Derulo insists his split from Jordin Sparks is permanent. The 'Talk Dirty' hitmaker, who recently ended his relationship with the 'No Air' singer after three years of dating, has ruled out getting back together...
Read more on Celebrity Balla
 
Josh Groban feels 'very lucky' to be dating Kat Dennings
Josh Groban feels ''very lucky'' to be dating Kat Dennings. The 'Brave' hitmaker was very nervous before singing in front of the '2 Broke Girls' actress for the first time at the Carousel of Hope Ball in Beverly Hills,...
Read more on Celebrity Balla
 
Australian Richard Flanagan wins 2014 Man Booker prize
London, Oct 15 (IANS) The first Man Booker prize to allow American nominees was Tuesday night won by an Australian, with Richard Flanagan triumphing for a novel of love and war that tells the harrowing stories of...
Read more on Celebrity Balla